NCE-1 Intelligence & Market Opportunity

Voranigo

Vorasidenib

Anticancer

Oral Tablets

Voranigo is an oral treatment for adults and teens with Grade 2 astrocytoma or oligodendroglioma that carry an IDH1 or IDH2 mutation, used after surgery. It blocks mutant IDH enzymes to slow tumor progression, significantly extending the time before disease worsens

Approval Date

06-Aug-24

NCE-1 Date

06-Aug-28

NCE Date

06-Aug-29

Commercial snapshot

Market performance & projections

Revenue ($M)

561

CAGR (%)

0.4899

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1385

2027

2006

2028

2417

2029

2764

2030

3070

2031

3391

2032

3673

Molecule profile

Details & specifications

Molecule

Vorasidenib

Innovator

SERVIER PHARMACEUTICALS LLC

Dosage Form

Oral Tablets

Strength

10 mg and 40 mg

Therapeutic Category

Anticancer

Usage

To treat grade 2 astrocytoma or oligodendroglioma

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.